Search results
Added:
2 years ago
ECO 2024 — Dr Donna H Ryan (Pennington Biomedical Research Center, US) joins us to discuss the first sub-analysis of the landmark SELECT trial (NCT03574597, Novo Nordisk).In this study, investigators looked at long-term weight loss with semaglutide 2.4 mg compared to a placebo among 17,604 participants. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss compared to…
View more
Added:
11 months ago
ADA 25 - PATHWEIGH roadmap for implementing weight management into primary care eliminated a population weight gain trajectory.Dr Leigh Perreault (University of Colorado Anschutz Medical Campus, US) joins us remotely to discuss the PATHWEIGH trial, which investigated a process of care to facilitate and prioritize weight management in a primary care setting. PATHWEIGH focused on reducing excess…
View more
Added:
1 year ago
ESC HF 25 - Outcomes from a study investigating liver stiffness measurement as a non-invasive method to assess central venous pressure showed immediate results at bedside obtained in >4 minutes, with the procedure easily performed by a trained nurse.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses a pilot validation study investigating liver stiffness as a non-invasive…
View more
Obesity in Asia-Pacific
Added:
2 years ago
Review Article
Added:
11 months ago
ADA 2025 - Once-monthly MariTide treatment demonstrates around 15% average weight reduction at 52 weeks in patients with obesity, with or without type 2 diabetes.We are joined by Dr Harold Bays (L-MARC Research Center, Louisville, US) to discuss a 52-week, placebo-controlled, phase 2 randomised study (NCT05669599) investigating the efficacy, safety and tolerability of different doses of once…
View more
Added:
8 months ago
HFSA 25 - Sex-specific outcomes of tirzepatide in obesity-related HFpEF showed that at baseline, women with HFpEF had more severe heart failure symptoms.Dr Barry Borlaug (Mayo Clinic, US) joins us to discuss a prespecified secondary analysis from the SUMMIT trial, examining sex-specific effects of tirzepatide in patients with heart failure with preserved ejection fraction and obesity.The SUMMIT…
View more
Added:
12 months ago
ERA 2025 - Dr Ruben Nogueiras (University of Santiago de Compostela, Santiago, ES) joins us to discuss upcoming treatments that will soon be approved for the treatment of obesity, including dual agonists that will also target type two diabetes. As well as exploring the evolution of our understanding and classification of obesity, Dr Nogueiras shares his view of obesity a multifactorial disease…
View more
Added:
1 year ago
In this short interview, Dr Scott Harris (Chief Medical Officer of AltImmune Inc.) joins us to discuss the emerging role of glucagon-containing dual and triple agonists for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Dr Harris discusses the clinical need for these drugs, as well as an outline of the current evidence for the use of incretins in the…
View more
Added:
2 years ago
ECO 2024 — Prof Barbara McGowan (Guy's and St Thomas' Hospital & King's College, UK) joins us to discuss the findings from the STEP 10 trial (NCT05040971, Novo Nordisk).This Phase 3 randomised clinical trial investigated the efficacy and safety of subcutaneous semaglutide 2.4 mg (GLP-1 RA) in 181 participants with obesity (BMI greater than or equal to 30.0 kg/m^2) and prediabetes. The primary…
View more
Added:
10 months ago
Source:
Radcliffe CVRM
A secondary analysis of the SUMMIT trial has found that the benefits of tirzepatide on reducing the risk of cardiovascular death or worsening heart failure (HF) are consistent across all levels of obesity in patients with heart failure with preserved ejection fraction (HFpEF).¹ However, patients with a higher baseline body mass index (BMI) experienced greater improvements in exercise capacity and…
View more